Home | Lectus Therapeutics

Lectus Therapeutics Ltd is an emerging UK-based bio-pharmaceutical company, which began operations in the summer of 2003, specialising in the discovery and development of novel drugs for diseases associated with smooth muscle hyperreactivity.

Lectus Therapeutics will exploit the power of its proprietary functional proteomics platform, LEPTICSTM (Leveraged Enabling Proteomics Technology for Ion Channel Screening), and build on its knowledge of ion channels and protein-protein interactions, to develop next-generation ion channel modulators that offer important clinical and economic advantages over existing therapies.

Lectus Therapeutics Ltd’s management team have extensive expertise in ion channel drug discovery, proteomics, chemistry, biology, finance and legal affairs gained from considerable experience within the biotechnology and pharmaceutical industry.

The management team is also supported by a world-class core scientific advisory board.

2 August 2004

Lectus Therapeutics announces chemistry collaboration with Evotec OAI.

6 May 2004

Lectus Therapeutics announces strategic investment from Takeda Research Investment to advance discovery programmes for next-generation ion channel drugs.

3 November 2003

Lectus Therapeutics Ltd announces financing from the SULIS Seedcorn Fund.

Articles

13 January 2004

Bioventure View - Lectus Therapeutics: driving channels forwards.

Conferences

Meet Lectus Therapeutics at the following events:

European Partnering and Investment Conference (EPIC)

London, UK. 16 September 2004

12th Annual BioPartnering Europe

London, UK. 10-12 October 2004

IBC's 3rd International Ion Channel Drug Targets

San Diego CA, USA. 18-21 October 2004

Recent conferences:

Euro-Biotech Forum

Paris, France. 20-22 June 2004

ERBI's 6th Annual Cambridge Biopartnering Exchange

Cambridge, UK. 5-7 May 2004